# Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Study · id `cardio:ct-nct02081118` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02081118](<https://clinicaltrials.gov/study/NCT02081118>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02081118

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 209 participants.

## Technical summary

Registry record NCT02081118. Randomized; triple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2015-03 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 209 participants (enrolled count; ClinicalTrials.gov record NCT02081118, source copy `cardio:ctgov-nct02081118-2016-08-09`, retrieved 2026-10-26)
- Start date: 2014-02 (registry gives no type) (ClinicalTrials.gov record NCT02081118, source copy `cardio:ctgov-nct02081118-2016-08-09`, retrieved 2026-10-26)
- Primary completion: 2015-03 (actual) (ClinicalTrials.gov record NCT02081118, source copy `cardio:ctgov-nct02081118-2016-08-09`, retrieved 2026-10-26)
- Completion: 2015-04 (actual) (ClinicalTrials.gov record NCT02081118, source copy `cardio:ctgov-nct02081118-2016-08-09`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02081118, source copy `cardio:ctgov-nct02081118-2016-08-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02081118-2016-08-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): HM11260C
- Intervention (Drug): Placebo
- Lead sponsor: Hanmi Pharmaceutical Company Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hanmi Pharmaceutical Company Limited (`cardio:org-hanmi-pharmaceutical-company-limited`)

## Provenance

Content hash: ccc2ffc51f62d1d4d52f502228053c780816ba4c76bcc4d853ae503df2adf4c8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
